The Impact of Central Corneal Thickness on Long-Term Medication Efficacy

We analyzed anonymized population datasets across 30 clinics to understand how baseline CCT correlates with resistance to prostaglandin analogues over a 5-year treatment lifecycle.

Central Corneal Thickness (CCT) is a well-established independent risk factor for the development and progression of Primary Open Angle Glaucoma (POAG). However, our data science team wanted to investigate if CCT also played a role in long-term pharmacological resistance.

The Study Parameters

Using Glaucoma One's anonymized population health aggregate tools, we isolated 12,000 patient records matching the following criteria:

• Diagnosed with POAG for at least 5 years.
• Monotherapy with a Prostaglandin Analogue (e.g., Latanoprost) for the duration.
• Reliable baseline CCT measurements recorded prior to therapy induction.

Key Findings

Patients with thin corneas (<520µm) demonstrated a 14% higher rate of medication resistance (defined as requiring adjunct therapy or surgery to maintain target IOP) by Year 4 compared to the median group.

While the exact mechanism involves complex biomechanical properties affecting both true IOP and trabecular meshwork outflow facilities, the clinical takeaway is clear: thin cornea patients require significantly tighter observation protocols and earlier consideration for multidrug therapy.